Abstract: The present invention provides novel JNK activating phosphatase polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing JNK activating phosphatase polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with JNK activating phosphatase polypeptides.
Type:
Grant
Filed:
March 18, 2004
Date of Patent:
March 27, 2007
Assignees:
Amgen Corporation, Baylor College of Medicine
Inventors:
John W. Belmont, Frederick A. Fletcher, Alice J. Chen, Roland Jurecic, Tse-Hua Tan, Guisheng Zhou
Abstract: This invention relates generally to methods and apparatus for desorption and ionization of analytes for the purpose of subsequent scientific analysis by such methods, for example, as mass spectrometry or biosensors. More specifically, this invention relates to the field of mass spectrometry, especially to the type of matrix-assisted laser desorption/ionization, time-of-flight mass spectrometry used to analyze macromolecules, such as proteins or biomolecules. Most specifically, this invention relates to the sample probe geometry, sample probe composition, and sample probe surface chemistries that enable the selective capture and desorption of analytes, including intact macromolecules, directly from the probe surface into the gas (vapor) phase without added chemical matrix.
Abstract: The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention.
Type:
Grant
Filed:
January 3, 2003
Date of Patent:
March 20, 2007
Assignees:
Baylor College of Medicine, Johns Hopkins University, University of Utah Research Foundation, United States of America, Represented by the Secretary, Department of Health and Human Services, c/o National Institute of Health
Inventors:
Rando Allikmets, Kent L. Anderson, Michael Dean, Mark Leppert, Richard A. Lewis, Yixin Li, James R. Lupski, Jeremy Nathans, Amir Rattner, Noah F. Shroyer, Nanda Singh, Philip Smallwood, Hui Sun
Abstract: The present invention provides mice having reduced CAR receptor activity and mice expressing a human CAR receptor. These mice are useful in screening methods to identify compounds that modulate CAR receptor activity, compounds likely to have CAR-mediated toxicity, and analogs of these compounds with less potential toxicity.
Abstract: The present invention provides compositions and methods for aiding in the diagnosis, monitoring and prognosis of SLE in a subject and for identifying potential therapeutic agents to treat and/or ameliorate the symptoms associated with SLE. Accordingly, embodiments of the invention are directed to methods of identifying the gene expression profile of a suitable sample by screening for the presence of a differentially expressed SLE-associated gene isolated from a sample containing or suspected of containing a cell that can differentially express an SLE-associated gene.
Type:
Application
Filed:
September 15, 2005
Publication date:
March 15, 2007
Applicant:
Baylor Research Institute
Inventors:
Marla Pascual, Jacques Banchereau, Lynda Bennett
Abstract: The present invention includes a method, a kit and an apparatus for prompting a user of an urination event. The present invention includes a portable incontinence prompting apparatus having a timer mechanism for timing an interval disposed within a housing and a time interval selection mechanism in communication with the timer mechanism for selecting a preset time interval. The apparatus includes a prompting mechanism in communication with the timer mechanism for issuing a prompting signal in response to a signal from the timer timing mechanism.
Abstract: The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention.
Type:
Grant
Filed:
January 3, 2003
Date of Patent:
March 13, 2007
Assignees:
Baylor College of Medicine, The United States of America as represented by the Department of Health and Human Services, University of Utah Research Foundation, John Hopkins University
Inventors:
Rando Allikmets, Kent L. Anderson, Michael Dean, Mark Leppert, Richard A. Lewis, Yixin Li, James R. Lupski, Jeremy Nathans, Amir Rattner, Noah F. Shroyer, Nanda Singh, Philip Smallwood, Hui Sun
Abstract: A new strategy for the quantitative determination of enantiomeric purity that combines guest-host complexation, spectroscopy, and chemometric modeling. Spectral data for samples of known enantiomeric composition is subjected to a type of multivariate regression modeling known as partial least squares (“PLS-1”) regression. The PLS-1 regression produces a mathematical model that can be used to predict the enantiomeric composition of a set of samples of unknown enantiomeric purity.
Type:
Grant
Filed:
December 3, 2004
Date of Patent:
March 13, 2007
Assignee:
Baylor University
Inventors:
Kenneth W. Busch, Isabel Maya P. Swamidoss, Sayo Fakayode, Marianna Busch
Abstract: The present invention provides mice having reduced CAR receptor activity and mice expressing a human CAR receptor. These mice are useful in screening methods to identify CAR ligands, including compounds that modulate CAR receptor activity, compounds likely to have CAR-mediated toxicity, and analogs of these compounds with less potential toxicity.
Type:
Grant
Filed:
October 10, 2002
Date of Patent:
March 6, 2007
Assignee:
Baylor College of Medicine
Inventors:
David D. Moore, Ping Wei, Steven S. Chua
Abstract: The present invention provides an inflow cannula tip that is shaped to prevent suction with the ventricular wall and adapted to prevent platelet adhesion. In particular, the inlet portion of the cannula tip comprises two projections extending from the cylindrical body of the cannula tip with gaps between the projections. The projections may have beveled edges. The inlet portion of the cannula tip can accept blood flow from either the gaps in the side or from the bottom of the tip. Even if the edge of the cannula tip is close to or even touching ventricle wall, a suction condition will not result, as blood is allowed to flow through the gaps between the projections.
Type:
Application
Filed:
September 25, 2006
Publication date:
March 1, 2007
Applicants:
Miwatec Co., Ltd., Baylor College of Medicine
Abstract: Methods and apparatus for modifying the bone portion of a graft, such as that used in the reconstruction of a damaged anterior cruciate ligament. Embodiments of the present invention comprise a driving member for threaded engagement with a housing member and a cutting member engaged with the driving member. The housing member is capable of receiving and supporting the bone graft without damaging a ligament attached thereto. Upon rotation of the driving member, the cutting member will engage the bone portion of the graft and modify it to have a generally circular cross section.
Abstract: Inadequate growth due to deficiencies in growth hormone (GR), growth hormone releasing hormone (GHRH), or genetic diseases can be ameliorated utilizing recombinant protein therapy with a novel GHRH analog having a sequence (SEQ ID NO:1). Also included is (1) a method of treating growth hormone-related deficiencies associated with the growth hormone pathway; (2) a method for treating growth hormone-related deficiencies associated with genetic disease; (3) a method to improve growth performance in an animal; (4) a method of treating an animal having a growth deficiency disease; (5) a method of increasing the efficiency of an animal used for food; and (6) a method to enhance growth in an animal.
Type:
Grant
Filed:
October 1, 2002
Date of Patent:
January 23, 2007
Assignee:
Baylor College of Medicine
Inventors:
Robert J. Schwartz, Ruxandra Draghia-Alki
Abstract: A boat includes a hull, topsides with a cockpit therein. A top is provided having a perimeter contoured for engaging a topsides perimeter in a closed position and providing a canopy for the topsides in an open position. Linear actuators are provided for moving the top between the open and closed positions along with a motor mechanism for operating the linear actuation. A panel moveably attached to the top enables operator entry and exit from the boat with the top in the closed position through an access provided by the panel.
Abstract: The present invention provides methods for detecting an abnormal condition of a blood pump system based on the power consumption of the pump actuator. By plotting differentiated power consumption of the pump actuator over time against the power consumption, a plot pattern is obtained. A change of the plot pattern area and/or a movement of the plot pattern will indicate a change in condition of the pump. A Heart Pump Area (HPA) index may be established which corresponds to the changing area of the plot pattern over time. A Heart Pump Position (HPP) index may be established which corresponds to the changing position of the plot pattern over time (e.g., corresponding to the distance the plot pattern has moved). By plotting the HPA index against the HPP index, changes in the condition of the pump can be monitored and any abnormal condition of the pump can be detected.
Type:
Grant
Filed:
September 3, 2003
Date of Patent:
January 2, 2007
Assignees:
Miwatec Co., Ltd., Baylor College of Medicine
Abstract: The invention relates to bone compression devices and bone compression systems, and in particular, to bone compression devices and systems for use in connection with vertebrae. The bone compression devices and bone compression systems are disposed, or installed, along at least one bone to maintain the at least one bone in a desired spatial relationship. Broadly, the invention is directed to a bone compression device for placing in communication with at least one bone having a bone radius of curvature, the bone compression device comprising a plate having a pre-formed shape, a deformed shape, and at least one elastic shape therebetween, the pre-formed shape having a pre-formed radius of curvature less than the bone radius of curvature, the deformed shape having a deformed radius of curvature greater than the bone radius of curvature, and at least one of the at least one elastic shapes having an elastic radius of curvature that substantially corresponds to the bone radius of curvature.
Abstract: A discrete segmented balloon catheter for removal of an embolus. In an embodiment, the catheter comprises a catheter having a proximal and a distal end, a fluid inlet at the proximal end, and discrete expandable segments placed along the shaft of the catheter. In addition, the segments are expanded through dispersal of fluid that flows from the catheter's proximal inlet. It follows that the segments are contracted through withdrawal of fluid from the catheter's proximal inlet.
Abstract: The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention.
Type:
Grant
Filed:
January 10, 2003
Date of Patent:
November 28, 2006
Assignees:
University of Utah Research Foundation, Baylor College of Medicine, John Hopkins University, The United States of America as represented by the Department of Health and Human Services
Inventors:
Rando Allikmets, Kent L. Anderson, Michael Dean, Mark Leppert, Richard A. Lewis, Yixin Li, James R. Lupski, Jeremy Nathans, Amir Rattner, Noah F. Shroyer, Nanda Singh, Philip Smallwood, Hui Sun
Abstract: The present invention relates to methods of intracellular delivery of oligonucleotides. More particularly, the present invention relates to the use of the delivery system to deliver G-quartet oligonucleotides as a cancer therapy or an anti-viral therapy.
Abstract: The present invention is related to TEX14 and germ cell intercellular bridges and compositions thereof that can be used to inhibit and/or decrease the activity and/or expression of TEX14 and/or disrupt the formation, function, and/or integrity of the intercellular bridges, including localization of key components to the intercellular bridge, for example. In particular aspects, the methods and compositions are employed for fertility and infertility applications.
Type:
Application
Filed:
March 30, 2006
Publication date:
October 5, 2006
Applicant:
BAYLOR COLLEGE OF MEDICINE
Inventors:
Martin Matzuk, Michael Greenbaum, Aleksandar Rajkovic
Abstract: The DNA and amino acid sequences are disclosed for a ligand (EDA1-II) and receptor (dl in mice and DL in humans) involved in ectodermal dysplasia. Also disclosed are variant DNA and amino acid sequences, and therapeutic applications of the ligands and receptors.
Type:
Grant
Filed:
December 4, 2000
Date of Patent:
October 3, 2006
Assignees:
Baylor College of Medicine, Oregon Health & Science University
Inventors:
Jonathan Zonana, Betsy M. Ferguson, Denis Headon, Paul Overbeek